Syndax Pharmaceuticals, Inc.SNDXNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 95% recommend buying.

Consensus Rating

Buy

21 analysts·High coverage

95%

Rating Distribution

Strong Buy

00%

Buy

2095%

Hold

15%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 83% higher.

Bear Case

$35.00

+64%

Consensus

$39.00

+83%

Bull Case

$44.00

+106%

Price Range21 analysts

Low

Consensus

High

$35.00

$44.00

Current Target

Current Price

$21.35

Upside to Target

$17.65

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-1.57(9 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+60.25%

EPS—

FY2028

Rev+37.28%

EPS+1195.76%

FY2029

Rev+31.23%

EPS+77.18%

Earnings Surprises

Beat rate:83%(10/12 quarters)

Avg surprise:+7.5%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Nov 24, 2025Barclays

Syndax price target raised to $35 from $22 at Barclays

Target:$35.00

+100.7%from $17.44

Nov 4, 2025UBS

Syndax price target raised to $38 from $35 at UBS

Target:$38.00

+176.2%from $13.76

Nov 4, 2025Barclays

Syndax price target raised to $22 from $19 at Barclays

Target:$22.00

+59.9%from $13.76

Sep 10, 2025Stifel Nicolaus

Syndax resumed with a Buy at Stifel

Target:$44.00

+179.7%from $15.73

Jul 15, 2025UBS

Syndax price target lowered to $35 from $37 at UBS

Target:$35.00

+257.3%from $9.79

Jul 10, 2025Goldman Sachs

Syndax initiated with a Buy at Goldman Sachs

Target:$18.00

+83.3%from $9.82

Nov 13, 2024Scotiabank

Syndax Pharmaceuticals (SNDX) PT Lowered to $18 at Scotiabank

Target:$18.00

-10.2%from $20.04

Oct 24, 2024UBS

UBS Starts Syndax Pharmaceuticals (SNDX) at Buy

Target:$37.00

+99.6%from $18.54

Aug 15, 2024Citigroup

Syndax Pharmaceuticals (SNDX) PT Raised to $34 at Citi

Target:$34.00

+69.2%from $20.09

Aug 15, 2024Bank of America Securities

Syndax price target raised to $31 from $30 at BofA

Target:$31.00

+58.3%from $19.58

Aug 15, 2024Barclays

Syndax price target raised to $33 from $32 at Barclays

Target:$33.00

+68.5%from $19.58

Jul 30, 2024Bank of America Securities

Syndax Pharmaceuticals (SNDX) PT Lowered to $30 at BofA Securities

Target:$30.00

+36.4%from $21.99

Jun 28, 2024Jefferies

Jefferies Starts Syndax Pharmaceuticals (SNDX) at Buy

Target:$37.00

+82.1%from $20.32

May 9, 2024Stifel Nicolaus

Syndax Pharmaceuticals (SNDX) PT Raised to $40 at Stifel

Target:$40.00

+78.7%from $22.38

Jan 3, 2023J.P. Morgan

JP Morgan Initiates Coverage On Syndax Pharmaceuticals with Overweight Rating, Announces Price Target of $41

Target:$41.00

+55.7%from $26.32

Dec 12, 2022Goldman Sachs

Goldman Sachs Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $39

Target:$39.00

+66.7%from $23.39

Dec 12, 2022H.C. Wainwright

HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $33

Target:$33.00

+59.9%from $20.64

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance